Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Antibiotics may do more than fight infection – new study investigates hidden effects

NCT ID NCT02707042

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how two common antibiotics (amoxicillin and azithromycin) affect the trillions of microbes living in healthy people. Researchers measured changes in metabolism, immune markers, and energy use before, during, and after a short course of antibiotics. The goal was to understand side effects beyond killing bacteria, not to treat any disease. 108 healthy adults aged 18-49 took part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

108 people

The number who actually took part.

Started

Mar 2017

Finished

May 2025

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 49 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* SUBJECT INCLUSION CRITERIA: Healthy women and men will be eligible for study participation if they meet the following criteria: * A participant will have passed his/her 18th birthday and will not have attained the age of 50 at the time of enrollment. * Willing to allow storage of their biological samples. * Able to comply with study procedures and swallow capsules. SUBJECT EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from study participation: * Body Mass Index (BMI) greater than or equal to 35 or less than or equal to 18 kg/M(2). * Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure \>160/100, oral temperature \>100 degrees F, pulse \>100. * Use of any of the following drugs or devices within the last 6 months: * systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral); * oral, intravenous, intramuscular, nasal, or inhaled corticosteroids; * cytokines; * methotrexate or immunosuppressive cytotoxic agents; * large doses of commercial probiotics consumed (greater than or equal to 10(8) cfu or organisms per day), including tablets, capsules, lozenges, chewing gum, or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, and foods do not apply. * anabolic steroids; * intrauterine device, combination hormone vaginal ring for contraception (due to unknown duration of local hormone effects), topical or systemic estrogens. Oral contraceptives with a standard 28-day cycle will be permitted if the subject has been consistently taking them for at least 1 month; * oral, topical, intramuscular testosterone preparations. * Illicit drug use, including amphetamines, cocaine, or heroin, within the last 6 months. Marijuana use is not exclusionary. * Chronic smokers and subjects who use smokeless tobacco products (due to known effects of tobacco on the oral microbiome). * Claustrophobia. * Use of antacids (proton pump inhibitors, sucralfate, H1 and H2 antagonists, and those containing aluminum magnesium) within the last 3 months. * Use of laxatives or enemas within the last 3 months. * Diagnostic colonoscopy within the last 6 months. * Use of topical antibiotics or topical steroids on the face, scalp, or neck, or on arms, forearms, or hands within the previous 30 days. * Use of vaginal/vulvar medications, including antifungals, within the previous 30 days. Subjects may continue to use permitted vaginal contraceptives (spermicides and female condoms) until 24 hours prior to sampling * Use of isotretinoin within the past 5 years. * Intranasal influenza vaccination within the last 6 months due to effects on mucosal immunity. * Acute disease at the time of enrollment (defer enrollment until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever. * Chronic, clinically significant (unresolved, requiring ongoing medical management or medication) pulmonary, cardiovascular, dermatologic, endocrine, GI, hepatic, or renal functional abnormality, as determined by medical history, physical examination, and/or laboratory testing. Includes, but not limited to: * A history of diabetes mellitus (Type 1 or 2), pituitary disease, hypothyroidism, hyperthyroidism * A history of physician-diagnosed asthma * A history of allergy to any antibiotic medications, including amoxicillin (penicillin) and/or azithromycin (macrolide) * A history of food allergy requiring dietary accommodation * Lactose-intolerance requiring dietary accommodation * A history of a bleeding disorder * Mononucleosis * Liver disease, including non-alcoholic fatty liver disease, AST or ALT \> 1.5 times normal value, cirrhosis * Renal disease, as defined by serum creatinine concentrations \> 1.5 mg/dL and/or overt proteinuria * Central nervous system disease, including previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders * Clinically significant abnormal results on electrocardiogram (ECG) that in the opinion of the PI, would place the patient at increased risk of QT-prolongation or other cardiac event * Genitourinary/Gynecologic conditions, including: * Treatment for or suspicion of ever having had toxic shock syndrome * History of hysterectomy or oophorectomy * History of condyloma or human papillomavirus diagnosed within the previous 2 years * History of candidiasis, urinary tract infection, or sexually transmitted disease (specifically chlamydia, gonorrhea, syphilis, genital herpes, trichomoniasis) diagnosed within the previous 6 months * Evidence (by history or physical exam) of vulvar or vaginal irritation at screening * History of vulvar, vaginal, or cervical dysplasia within the previous 5 years * History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision. * Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet. * Recent history of excessive alcohol consumption defined as more than five 1.5-ounce servings of 80-proof distilled spirits, five 12-ounce servings of beer, or five 5-ounce servings of wine at one sitting over the last 30 days. * Positive test for HIV, hepatitis B virus, or hepatitis C virus indicating infection (hepatitis B seropositivity conferred by vaccination is not exclusionary). * Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired). * Major surgery of the GI tract, including cholecystectomy or appendectomy, in the past 5 years. Any major bowel resection at any time. * History of gastric stapling, lap band, or surgical procedure for treatment of obesity. * History of GI disorders or diseases including: * inflammatory bowel disease (IBD) including ulcerative colitis, Crohn s disease (of any severity), or indeterminate colitis; * irritable bowel syndrome (IBS); * persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent), gastric or duodenal ulcer; * Celiac disease; * chronic constipation. * Active behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study, including major depression, anxiety disorder, schizophrenia, and presence of psychotic symptoms. * Active eating disorders, including anorexia nervosa, bulimia, or binge eating syndrome. * Use of weight-loss drugs within the past 5 years. * Weight change (intended or unintended; loss or gain) of more than 10% of total body weight in the 3 months before admission. * Regular urinary incontinence necessitating use of incontinence protection garments. * Female who is pregnant, intending to become pregnant, or lactating. * History of recurrent rashes within the past 6 months. * At the time of the screening visit: * multiple blisters, pustules, boils, abscesses, erosions or ulcers on the scalp, face, neck, arms, forearms, or hands; * uniformly thickened, cracking, dry skin on bilateral palms and/or soles; * disseminated rash (at multiple body sites or extending throughout a broad body area). * Subjects who are unable to complete required study visits per allotted visit windows. * Any condition that, in the opinion of the investigator, contraindicates participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.